The immune system is an intricate network composed of cells, tissues, and molecular pathways that safeguards the body against infectious agents while ensuring self-tolerance. It is primarily divided into two categories: the innate immune system, which provides immediate but non-specific defence, and the adaptive immune system, which delivers long-lasting, antigen-specific protection. Effective immune function depends on the harmonious interaction of various immune cells, including T cells, B cells, macrophages, dendritic cells, and natural killer (NK) cells. Critical mediators of immune responses include cytokines, antibodies, and the complement system. Although the immune system is adept at differentiating between self and non-self, lapses in immune regulation can lead to autoimmune diseases, where the immune system mistakenly targets the body’s own tissues. This failure in self-tolerance can be influenced by genetic factors, environmental triggers (such as infections, toxins, and stress), and irregularities in immune regulatory mechanisms. Important processes contributing to autoimmunity encompass molecular mimicry, loss of both central and peripheral tolerance, cytokine dysregulation, and epigenetic changes. Autoimmune diseases can be categorized as organ-specific, affecting certain tissues (e.g., type 1 diabetes, multiple sclerosis), or systemic, involving widespread immune activation (e.g., systemic lupus erythematosus, rheumatoid arthritis). Diagnostic and prognostic biomarkers, including autoantibodies, e.g., anti-nuclear antibody (ANA), anti-double stranded deoxyribonucleic acid (dsDNA), rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), inflammatory markers such as chain reactive protein (CRP), erythrocyte sedimentation rate (ESR), and cytokine profiles, are essential for the diagnosis, prognosis, and monitoring of these conditions. Recent therapeutic advancements have introduced targeted biologic therapies, monoclonal antibodies, and immune checkpoint inhibitors, transforming the treatment landscape for autoimmune diseases by selectively modulating immune pathways. Although these therapies have greatly enhanced patient outcomes, there are still challenges in comprehending disease variability, treatment resistance, and long-term adverse effects. Future investigations into personalized immunotherapy, gene editing, and microbiome-based treatments show potential for improving treatment strategies and preventing disease onset. A thorough understanding of immune regulation is crucial for creating innovative therapeutic methods and advancing precision medicine in the fields of immunology and autoimmunity.

Immunology and Autoimmunity: Current Concepts and Clinical Implications

章节
发表日期：

2026年

查看全文

Naseem Ahmed,
Aiyesha Humaira

摘要

The immune system is an intricate network composed of cells, tissues, and molecular pathways that safeguards the body against infectious agents while ensuring self-tolerance. It is primarily divided into two categories: the innate immune system, which provides immediate but non-specific defence, and the adaptive immune system, which delivers long-lasting, antigen-specific protection. Effective immune function depends on the harmonious interaction of various immune cells, including T cells, B cells, macrophages, dendritic cells, and natural killer (NK) cells. Critical mediators of immune responses include cytokines, antibodies, and the complement system. Although the immune system is adept at differentiating between self and non-self, lapses in immune regulation can lead to autoimmune diseases, where the immune system mistakenly targets the body’s own tissues. This failure in self-tolerance can be influenced by genetic factors, environmental triggers (such as infections, toxins, and stress), and irregularities in immune regulatory mechanisms. Important processes contributing to autoimmunity encompass molecular mimicry, loss of both central and peripheral tolerance, cytokine dysregulation, and epigenetic changes. Autoimmune diseases can be categorized as organ-specific, affecting certain tissues (e.g., type 1 diabetes, multiple sclerosis), or systemic, involving widespread immune activation (e.g., systemic lupus erythematosus, rheumatoid arthritis). Diagnostic and prognostic biomarkers, including autoantibodies, e.g., anti-nuclear antibody (ANA), anti-double stranded deoxyribonucleic acid (dsDNA), rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), inflammatory markers such as chain reactive protein (CRP), erythrocyte sedimentation rate (ESR), and cytokine profiles, are essential for the diagnosis, prognosis, and monitoring of these conditions. Recent therapeutic advancements have introduced targeted biologic therapies, monoclonal antibodies, and immune checkpoint inhibitors, transforming the treatment landscape for autoimmune diseases by selectively modulating immune pathways. Although these therapies have greatly enhanced patient outcomes, there are still challenges in comprehending disease variability, treatment resistance, and long-term adverse effects. Future investigations into personalized immunotherapy, gene editing, and microbiome-based treatments show potential for improving treatment strategies and preventing disease onset. A thorough understanding of immune regulation is crucial for creating innovative therapeutic methods and advancing precision medicine in the fields of immunology and autoimmunity.